Pharmacokinetic Properties and Systemic Safety of Vancomycin-Impregnated Cancellous Bone Grafts in the Treatment of Spondylodiscitis

Table 1

Demographic data, microbiological findings, and treatment information of 8 patients suffering from a spondylodiscitis and being treated with vancomycin-loaded, cancellous bone grafts.

Patient	1	2	3	4	5	6	7	8
Age/gender	73/F	65/M	61/M	73/F	75/F	83/F	77/F	43/M
Spondylodiscitis localization	L3/4	L4/5	Th 6/7	Th 8/9	L3/4	L2/3	Th12/L1	Th10-11
Pathogen organism	n.o.i.	S. hominis	S. epidermidis	E. cloacae	MRSA	E. coli	n.o.i.	S. aureus
Surgical therapy	One-stage anterior-posterior stabilization	One-stage anterior-posterior stabilization	Two-stage anterior-posterior stabilization	One-stage anterior-posterior stabilization	Two-stage anterior-posterior stabilization	One-stage anterior-posterior stabilization	Two-stage anterior-posterior stabilization	One-stage anterior-posterior stabilization
Implant used	VLIFT + AIBGs	AIBGs	VLIFT + AIBGs	VLIFT + AIBGs	AIBGs	AIBGs	AIBGs	VLIFT + AIBGs
Intravenous antibiotic therapy	Meronem + daptomycin	Levofloxacin	Cefuroxime + rifampicin	Ceftazidime + refobacin	Rifampicin + daptomycin	Cefotaxime	Clindamycin	Cefuroxime
Oral antibiotic therapy	Levofloxacin	Levofloxacin	Linezolid	Levofloxacin	Linezolid	Ciprofloxacine	Ciprofloxacine	Cefuroxime
Follow-up [months]	13	27	16	12	36	12	12	4

M: male; F: female; n.o.i.: no organism isolated; AIBGs: antibiotic-impregnated bone graft; MRSA: methicillin-resistant Staphylococcus aureus.